Managed Care Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Geron Corp.
Company inks agreement with Merck for cancer vaccines targeting telomerase
August 16th, 2005
Geron Corp. (GERN) announced it has entered into a collaboration and license agreement with Merck & Co., Inc., (MRK) to develop a cancer vaccine targeting telomerase utilizing Merck's expertise in vaccine technologies. Under the terms of the agreement, Geron will receive an upfront payment, milestone payments upon achievement of certain development and regulatory events, and royalties. Merck has also agreed to acquire equity in Geron at a future date as part of Geron's next round of financing. Additional financial terms were not disclosed. In addition, Merck has acquired an exclusive option to negotiate a separate agreement for Geron's dendritic...
Source: Managed Care Business Week (2005-08-16)
|
